Assessment of Patient-Derived Xenograft Growth and Antitumor Activity: The NCI PDXNet Consensus Recommendations
Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Jeffrey A. Moscow(National Cancer Institute), Soner Koc(Seven Bridges Genomics (United States)), Alana L. Welm(Huntsman Cancer Institute), Nicholas Mitsiades(Harvard University), Luis G. Carvajal‐Carmona(Cancer Research UK), Kurt W. Evans(The University of Texas MD Anderson Cancer Center), Jack A. Roth(The University of Texas MD Anderson Cancer Center), Larry Rubinstein(National Cancer Institute), Michael W. Lloyd(Smithsonian Institution), Michael T. Lewis(Baylor College of Medicine), Min Jin Ha(University of North Carolina at Chapel Hill), Lisa M. McShane(National Cancer Institute), James H. Doroshow(National Cancer Institute), Yvonne A. Evrard, Geoffrey I. Shapiro(Brigham and Women's Hospital), Michael A. Davies(The University of Texas MD Anderson Cancer Center), Huiqin Chen(The University of Texas MD Anderson Cancer Center), José G. Treviño(Virginia Commonwealth University), Anuj Srivastava(Baba Raghav Das Medical College), Xuelin Huang(The University of Texas MD Anderson Cancer Center), J. Chuck Harrell(Virginia Commonwealth University), Salma Kaochar(Baylor College of Medicine), D. Li(East China Normal University), Bryan E. Welm(University of Minnesota), Jeffrey H. Chuang(Boston College), Ryan C. Fields(Washington University in St. Louis), Kaushik Varadarajan(The University of Texas MD Anderson Cancer Center), Jing Wang(The University of Texas MD Anderson Cancer Center), Li Ding(Shenyang Agricultural University), Ramaswamy Govinden(Washington University in St. Louis), Dennis A. Dean(Seven Bridges Genomics (United States)), Meenhard Herylyn(The Wistar Institute), Jeffrey W. Grover(Seven Bridges Genomics (United States))
Cited by 21
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
|Journal of Clinical Oncology|2010|4.3k
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k
Somatic mutations affect key pathways in lung adenocarcinoma
|Nature|2008|2.8k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k